Home / Drug development / Preclinical / Process development
Process R&D services
We turn early discovery chemistry into scalable, phase-appropriate processes ready for IND-enabling studies and GMP manufacturing. Our pharmaceutical process development expertise ensures robust, reproducible routes that deliver high-purity material at the right scale – from grams to kilograms.
By integrating pre-IND scale-up with process optimisation, we reduce risk, shorten timelines, and keep your molecule moving confidently toward the clinic.
Capabilities include:
- Route scouting towards production on scale
- Early-phase process development and optimization
- Non-GMP material supply to support preclinical research
- Flow chemistry for efficient, continuous synthesis
- Biocatalysis screening and enzymatic transformations
- Chemo-catalysis and advanced catalytic methods
- Classical resolution and chiral separation techniques
- Optimal use of Design of Experiments (DoE), Bayesian optimization (AI) and high-throughput experimentation techniques.
- Seamless transfer into GMP manufacturing
Preclinical process expertise
Discovery-to-development transfer
Integrated process teams ensure smooth, risk-free transfer with fewer handoffs from early chemistry to scalable routes, keeping projects efficient, compliant and on track for GMP.
Specialized technologies
Expertise across flow chemistry, biocatalysis and chemo-catalysis techniques mean faster optimisation, cleaner chemistry and dependable results.
Integrated preclinical drug development
We bring process development together with our broader preclinical expertise to create a clear, connected path to the clinic.
We deliver IND scale-up, formulation and analytical development, and high-throughput solid-state chemistry work in concert to deliver stable, dose-ready material, allowing you to identify optimal forms early and reduce the risks and delays that can slow your program.
What do our partners say?
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
Your discovery and development partner that sees beyond
We partner with you from target exploration to IND, combining medicinal chemistry, assay biology, ADME-Tox, and CMC development. Our connected teams in Europe and North America work as one to ensure scientific continuity, open communication and steady progress across all phases of drug discovery and development.
Resources we think you'll love
Blog
When a clean PK profile is actually a warning sign
Blog
CDMO red flags you can’t ignore: Communication breakdowns
Blog
CDMO red flags you can’t ignore: Capacity constraints and resource stretch
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our preclinical process development experts
See how we can support the discovery and development of your next breakthrough.